Trials / Completed
CompletedNCT03984370
Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- University Hospital, Gentofte, Copenhagen · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The aim of this study is investigating the effect of a novel glucagon analogue administration in gastric bypass operated individuals, who are reactive hypoglycemic.
Detailed description
The Roux-En-Y gastric bypass (RYGB) has major health-promoting effects - reversing type-2-diabetes, improving dyslipidemia and inducing robust weight loss. However, several RYGB-individuals, post surgery, suffers from dumping syndrome and postprandial hyperinsulinemic hypoglycemia (PHH) due to the anatomical rearrangement of the gastro-intestinal system. Dasiglugaon (also known as (ZP4207) has shown great pharmacokinetic- and dynamic effects, compared to other glucagon analogues on the market, when administrated to hypoglycemic type-1-diabetics. Therefore we aim to examine the effects of two different doses of dasiglucagon on the postprandial nadir plasma glucose concentration in RYGB-operated individuals suffering from PHH by use of a mixed meal test (MMT). The study is designed as a double-blinded, randomised, 3-period, 3-treatment, crossover study comprising 3 separate treatment days in which participants will undergo an MMT along with one of the following double-blinded interventions: 1. Subcutaneous (sc) placebo (saline) injection 2. Sc injection with 80 μg dasiglucagon 3. Sc injection with 200 μg dasiglucagon
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZP4207 | Abdominal SC administration |
| OTHER | Placebo (saline) | Abdominal SC administration |
Timeline
- Start date
- 2019-09-18
- Primary completion
- 2020-02-26
- Completion
- 2020-02-26
- First posted
- 2019-06-13
- Last updated
- 2020-03-31
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT03984370. Inclusion in this directory is not an endorsement.